Analysts Offer Predictions for Elevance Health Q2 Earnings

Elevance Health, Inc. (NYSE:ELVFree Report) – Stock analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Elevance Health in a research report issued on Thursday, January 30th. Zacks Research analyst K. Dey now expects that the company will post earnings of $9.85 per share for the quarter, down from their previous estimate of $10.35. The consensus estimate for Elevance Health’s current full-year earnings is $34.07 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $5.31 EPS, FY2025 earnings at $34.16 EPS, Q1 2026 earnings at $12.30 EPS, Q2 2026 earnings at $11.67 EPS, Q3 2026 earnings at $10.23 EPS, Q4 2026 earnings at $6.10 EPS and FY2026 earnings at $40.30 EPS.

Other equities analysts have also recently issued reports about the company. Argus reiterated a “hold” rating and issued a $405.40 price objective on shares of Elevance Health in a report on Wednesday, January 29th. Mizuho cut their target price on Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Truist Financial decreased their price target on shares of Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $485.00 price objective on shares of Elevance Health in a research note on Friday, January 24th. Finally, TD Cowen reduced their target price on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $517.03.

View Our Latest Analysis on ELV

Elevance Health Stock Down 0.7 %

Shares of NYSE:ELV opened at $402.29 on Monday. The firm has a market capitalization of $93.30 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 1.19 and a beta of 0.83. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health has a 52-week low of $362.21 and a 52-week high of $567.26. The firm has a fifty day moving average of $386.45 and a 200 day moving average of $456.00.

Elevance Health (NYSE:ELVGet Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%.

Institutional Trading of Elevance Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELV. Centaurus Financial Inc. boosted its stake in shares of Elevance Health by 66.9% during the 2nd quarter. Centaurus Financial Inc. now owns 918 shares of the company’s stock valued at $498,000 after purchasing an additional 368 shares in the last quarter. Czech National Bank lifted its holdings in Elevance Health by 6.7% in the third quarter. Czech National Bank now owns 47,237 shares of the company’s stock worth $24,563,000 after buying an additional 2,947 shares during the period. Handelsbanken Fonder AB boosted its position in Elevance Health by 4.1% during the 3rd quarter. Handelsbanken Fonder AB now owns 75,320 shares of the company’s stock valued at $39,166,000 after acquiring an additional 2,987 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Elevance Health by 19.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,098 shares of the company’s stock worth $1,611,000 after acquiring an additional 502 shares during the period. Finally, Chemistry Wealth Management LLC raised its position in shares of Elevance Health by 4.0% in the 3rd quarter. Chemistry Wealth Management LLC now owns 6,793 shares of the company’s stock worth $3,533,000 after acquiring an additional 261 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend is Monday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s dividend payout ratio is currently 25.46%.

About Elevance Health

(Get Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

See Also

Earnings History and Estimates for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.